Speedier drug approvals hit slowdown as FDA faces scrutiny

Dec 6, 2022, 7:01 AM | Updated: 9:03 pm
FILE - A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Si...

FILE - A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. Expedited drug approvals slowed in 2022, as the FDA's controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders. With less than a month remaining in the year, the agency’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs. (AP Photo/Manuel Balce Ceneta, File)

(AP Photo/Manuel Balce Ceneta, File)

WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.

With less than a month remaining in the year, the FDA’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs.

The program allows drugs to launch in the U.S. based on promising early results, before they are proven to benefit patients.

Academics have long complained that the practice has resulted in a glut of expensive, unproven medications, particularly for cancer. But last year’s accelerated approval of a much-debated Alzheimer’s drug touched off a new round of criticism, including investigations of FDA’s decision making by federal inspectors and Congress.

A recent FDA hearing aimed at revoking approval from an unproven preterm birth drug further underscored the program’s shortcomings. FDA has been trying to get the drug, Makena, off the market for more than two years, because a follow-up study showed it didn’t benefit infants or mothers. The manufacturer has refused to cooperate.

Amid the latest controversy, FDA leaders have taken unprecedented steps suggesting a tougher stance on accelerated approval: nudging drugmakers to remove a growing list of unproven uses for drugs and asking Congress for new powers to expedite removals when companies balk.

Dr. Reshma Ramachandran, a Yale University researcher who supports congressional reforms, believes the recent scrutiny of the accelerated approval process “definitely led to them pausing and taking a different path.” Still, Ramachandran and other critics say it’s too early to tell if FDA’s recent actions reflect a longer-term policy shift.

An FDA spokeswoman said the agency’s posture on accelerated approval “has remained consistent and the agency is committed to ensuring the integrity of the program.” She added that FDA is using “every authority at our disposal” to make sure drugmakers quickly conduct confirmatory studies after approval.

Launched in 1992, the accelerated approval program is credited with speeding the availability of early breakthroughs for HIV and cancer. About 300 drug approvals have been made that way, nearly half of them in the last five years.

But researchers and government watchdogs have chronicled problems with FDA’s oversight, including delays in quickly removing drugs with failed or missing confirmatory studies. Federal inspectors recently found that 40% of accelerated approvals had incomplete confirmation studies.

The picture is beginning to change. In less than two years, the FDA has successfully called on drugmakers to remove more than 20 approvals from accelerated drugs — mainly cancer therapies — that failed to show a benefit. That’s more than half the withdrawals in the program’s history.

FDA’s cancer chief, Dr. Rick Pazdur, has referred to this effort of clawing back approvals as his “jihad.”

Several drugmakers recently declined FDA requests to voluntarily pull their drugs. That’s raised the specter of more long, onerous public hearings to force removal, a process Pazdur called “a nightmare.”

The ability to require drugmakers to have their studies underway before approval is one part of legislation that congressional lawmakers hope to attach to a massive, end-of-the-year spending bill. If passed, it would be the biggest overhaul in accelerated approval’s 30-year history.

“We need more teeth in terms of getting the confirmatory trials started before accelerated approval,” FDA Commissioner Robert Califf said at a recent cancer conference. “Once approval occurs it’s very difficult to hold back the marketeers.”

FDA regulators are already testing out the approach. Increasingly, the agency is telling drugmakers they must have their confirmation studies underway before approval.

“We know the FDA has raised the bar for accelerated approval, and so that’s why we’re seeking additional clarity on their position,” Mike Sherman, CEO of startup Chimerix, told investors on a recent call discussing the company’s plans for an upcoming cancer drug.

A higher bar could spell trouble for smaller drugmakers, who often rely on accelerated approval to gain a market foothold before raising additional funds.

To be sure, FDA approval trends are impacted by a variety of forces. The agency’s overall tally of novel drugs is down markedly this year at about 30, compared with 50 last year. And even the recent peak in use of the accelerated pathway — 45 approvals in 2020 — reflected several trends.

Drugmakers have been aggressively pursuing a new class of “immunotherapies” that help the body recognize and attack cancer. The FDA has granted more than 80 uses for those drugs since 2015, pushing up annual accelerated approval tallies.

Additionally, COVID-19 pandemic disruptions forced some drugmakers to cut short their research plans, asking FDA for accelerated approval based on partially completed studies, instead of a full results.

“There was a lot of reinterpretation of the FDA rules to make sure those companies could proceed, otherwise they would have lost billions of dollars,” said Sam Kay, a consultant with Clarivate, which advises pharmaceutical companies.

It’s a reminder of how much flexibility the FDA has.

Many of the reforms pending in Congress “are things the FDA could do now,” notes Ramachandran.

“I think having Congress do it gives them the cover and blessing to carry forward with what they want to do,” she said.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Muslim protesters burn posters during a rally outside the Swedish Embassy in Jakarta, Indonesia, Mo...
Associated Press

Indonesian Muslims protest Quran burning in Sweden

JAKARTA, Indonesia (AP) — Hundreds of Indonesian Muslims marched to the heavily guarded Swedish Embassy in the country’s capital on Monday to denounce the recent desecration of Islam’s holy book by far-right activists in Sweden and the Netherlands. Waving white flags bearing the Islamic declaration of faith, more than 300 demonstrators filled a major thoroughfare […]
1 day ago
Associated Press

Report: Slovenia authorities detain 2 alleged Russian spies

LJUBLJANA, Slovenia (AP) — Slovenian authorities have apprehended two alleged Russian spies who used an agency dealing in real estate and antiques as a front for their activities, media reported Monday. Slovenia’s respected Delo newspaper and the Siol news portal cited the public prosecutor’s office as confirming the arrests. According to the media outlets, the […]
1 day ago
FILE - Protestors march during a demonstration against pension changes, Thursday, Jan. 19, 2023 in ...
Associated Press

France braces for major transport woes from pension strikes

PARIS (AP) — France’s national rail operator is recommending that passengers stay home Tuesday to avoid strikes over pensions that are expected to cause major transport woes but largely spare high-speed links to Britain, Belgium and the Netherlands. Labor unions that mobilized massive street protests in an initial salvo of nationwide strikes earlier this month […]
1 day ago
India's opposition Congress party leader Rahul Gandhi, center right and his sister and party leader...
Associated Press

Indian opposition’s ‘unity march’ ends in disputed Kashmir

SRINAGAR, India (AP) — India’s main opposition Congress party ended a five-month cross-country “unity march” in disputed Kashmir on Monday with hundreds of members of various opposition groups joining in a public rally in freezing temperatures. The march led by Rahul Gandhi, an opposition leader and scion of the influential Gandhi family, sought to challenge […]
1 day ago
FILE - Visitors wearing face masks talk near a display for Chinese online retailer JD.com at the Ch...
Associated Press

Chinese e-retailer JD.com leaving Thailand, Indonesia

BEIJING (AP) — Chinese online retailer JD.com Inc. is pulling out of Indonesia and Thailand amid intense competition in Southeast Asia. JD.com will stop taking orders Feb. 15 in both countries and shut down the following month, according to announcements Monday on the two websites. The company gave no reason for the closures, but e-commerce […]
1 day ago
Associated Press

German economy shrank 0.2% in Q4, worse than expected

BERLIN (AP) — Germany’s economy shrank by 0.2% in the fourth quarter compared with the previous three-month period, official figures showed Monday. The performance by Europe’s biggest economy was worse than expected. Gross domestic product shrank for the first time since the first quarter of 2021 largely because of a decline in consumer spending, which […]
1 day ago

Sponsored Articles

safety from crime...

As crime increases, our safety measures must too

It's easy to be accused of fearmongering regarding crime, but Seattle residents might have good reason to be concerned for their safety.
Comcast Ready for Business Fund...
Ilona Lohrey | President and CEO, GSBA

GSBA is closing the disparity gap with Ready for Business Fund

GSBA, Comcast, and other partners are working to address disparities in access to financial resources with the Ready for Business fund.
SHIBA WA...

Medicare open enrollment is here and SHIBA can help!

The SHIBA program – part of the Office of the Insurance Commissioner – is ready to help with your Medicare open enrollment decisions.
Lake Washington Windows...

Choosing Best Windows for Your Home

Lake Washington Windows and Doors is a local window dealer offering the exclusive Leak Armor installation.
Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Speedier drug approvals hit slowdown as FDA faces scrutiny